Nextcure opened lower at $5.95, compared with its previous close of $5.98. In the last trading session, the stock traded between $5.37 and $6.36. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Nextcure is now worth
$ 7.68
Resulting in a loss of
$ 92.32 (92.32%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.12 (+2.07%)
Day High
$6.36
Day Low
$5.37
Day Open
$5.95
Prev Close
$5.98
Volume
41,528
1W Return
4.04%
1M Return
-9.92%
3M Return
-9.77%
6M Return
-37.59%
1Y Return
-28.36%
Fundamentals
Market Cap ($ Mn)
28
PE Ratio
-
PB Ratio
2.01
PEG Ratio
-
ROE
-131.98%
ROCE
-117.41%
EPS (TTM)
$-3.66
Investment Returns
1 Week
4.04%
1 Month
-9.92%
3 Months
-9.77%
6 Months
-37.59%
9 Months
-51.17%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
11Nov
NextCure Q3 Results: Loss narrows to $1.29 per share, beats estimates
Reported loss of $1.29 per share in Q3. Beat analyst consensus estimate of $1.43 by 9.79%. Loss narrowed 59.94% YoY from $3.22 per share.
NextCure’s Q2 EPS of $(2.80) missed estimates by 45.08%, with losses widening 75.2% YoY compared to $(11.29) per share. The results signal continued pressure on profitability metrics against analyst expectations.
3mo ago
21Jul
Ademi LLP investigates NextCure merger fairness to shareholders
Ademi LLP has launched an investigation into NextCure Inc's merger with Avere Therapeutics to determine if the board breached fiduciary duties. The deal leaves NextCure shareholders with 1.21% ownership and includes a $320 million private placement. The firm is scrutinizing the fairness of the process and potential conflicts of interest.
